Skip to main content
PIQRAY header image

PIK3CA is the most commonly mutated gene in HR+/HER2- aBC2

 

Patients with a PIK3CA mutation can have:

PIK3CA mutation prognosis statistics

mPFS, median progression-free survival.

Why does the PIK3CA mutation matter?

Experts Dr Dejan Juric, Dr Jules Cohen, and Dr Chaitali Nangia discuss the significance of PIK3CA in aBC and why testing for mutation status may impact treatment decisions.

View more expert videos 

Important Safety Information

PIQRAY is contraindicated in patients with severe hypersensitivity to it or any of its components. 

Severe Hypersensitivity: Severe hypersensitivity reactions, including anaphylaxis and anaphylactic shock, can occur in patients treated with PIQRAY. Severe hypersensitivity reactions were manifested by symptoms including, but not limited to, dyspnea, flushing, rash, fever, or tachycardia...

Indication

PIQRAY® (alpelisib) tablets is indicated in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer as detected by an FDA-approved test following progression on or after an endocrine-based regimen...

Click or scroll to see IMPORTANT SAFETY INFORMATION AND INDICATION

References: 1. Mosele F, Stefanovska B, Lusque A, et al. Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer. Ann Oncol. 2020;31(3):377-386 2. The Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61-70. 3. Data on file. Novartis Pharmaceuticals Corp; 2021. 4. Mollon LE, Anderson EJ, Dean JL, et al. A systematic literature review of the prognostic and predictive value of PIK3CA mutations in HR+/HER2- metastatic breast cancer. Clin Breast Cancer. 2020;20(3):e232-e243.